TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06151314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implants.
Description: 5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implants.
Description: 5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
Study: NCT06408948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SHR7280
Description: Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
Study: NCT05201196

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination \& pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Oriented Training
Description: Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins
Study: NCT06199063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Streching Exercises
Description: The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation Exercises
Description: The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reciprocal-Inhibiton Exercises
Description: The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
Study: NCT06414720

Intervention type: DRUG
Intervention: Dienogest 2 MG
Description: The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
Study: NCT04810286

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3d-Printing Myofunctional Appliance
Description: To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3d-Printing Myofunctional Appliance
Description: To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
Study: NCT05943808

Intervention type: OTHER
Intervention: Book reading
Description: subjects are given an acupuncture textbook to read for 30 minutes

Intervention type: OTHER
Intervention: VR pre-recorded video watching
Description: subjects are given an pre-recorded VR video to watch for 30 minutes
Study: NCT05747209

Intervention type: OTHER
Intervention: Observation of Exercise Program Adherence
Description: Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
Study: NCT04786990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: Viloxazine extended-release capsule
Study: NCT06446167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MLS Laser Treatment
Description: The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESWT treatment
Description: The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions
Study: NCT04757376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P41
Description: 60 mg/mL single dose, Solution for injection in PFS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Prolia
Description: 60 mg/mL single dose, Solution for injection in PFS
Study: NCT03621397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brainHQ by Posit Science
Description: This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
Study: NCT05627791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
Study: NCT06387277

Intervention type: OTHER
Intervention: RV1551P GB3224
Description: RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9).
Study: NCT04694157

Intervention type: DEVICE
Intervention: cardiac shock wave therapy
Description: Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
Study: NCT04629976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCO-48 Fumarate 4 mg
Description: 2 x 2mg NCO-48 Fumarate over 28 days of therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCO-48 Fumarate 20 mg
Description: 2 x 10 mg NCO-48 Fumarate over 28 days of therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide 25 mg
Description: 25 mg over 28 days of therapy
Study: NCT05769907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
Study: NCT06507228

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NWL PEBBLE STT
Description: At home testing for OSA with AcuPebble.
Study: NCT06005038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pSOPT
Description: computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MLA
Description: computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
Study: NCT05537506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracket slot 0.018
Description: That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracket slot 0.022
Description: Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
Study: NCT05104788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
Study: NCT05896410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: splint (orthosis)
Description: 3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint (orthosis)
Description: 3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
Study: NCT06482255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and therapeutic exercise
Description: * Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy and therapeutic exercise and virtual reality
Description: * Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality
Study: NCT05856279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mulligan SNAG and mulligan lion position
Description: manual therapy techniques for lumbar spine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mulligan SNAG and mulligan lion position
Description: manual therapy techniques for lumbar spine
Study: NCT06158256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary apnoea
Description: Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
Study: NCT04998292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezo-surgery with low level laser therapy
Description: Low level laser therapy
Study: NCT05398224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Description: Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients \>65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion.
Study: NCT05591872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD+I+TRB
Description: Same as in the arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD+I+TRB
Description: Same as in the arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD+I+TRB
Description: Same as in the arm description
Study: NCT06403124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Open reduction and internal fixation by reconstruction plate and screws
Study: NCT04998292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Piezo-surgery only
Description: Piezo-surgery only
Study: NCT06438744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture (TEA) + standard therapy
Description: * TEA : one-time TEA using 30 gauge TEA needle with 30 mm polydioxanone thread at CV3 through CV4, SP6 and ST36 bilaterally~* Standard therapy : 2 mg dienogest daily for 8 weeks after TEA
Study: NCT06247449

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain imaging
Description: Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of circulating tumor DNA
Description: One single blood draw for analysis of circulating tumor DNA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing Morbidities Index
Description: Questionnaire regarding the participant's perception of brain imaging.
Study: NCT05288244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
Description: To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
Description: To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
Description: To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
Study: NCT04294862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: TNP-2092 for injection 100mg/vial
Study: NCT06151301

Intervention type: DIAGNOSTIC_TEST
Intervention: serum procalcitonin
Description: predicting the severity of intoxication

Intervention type: DIAGNOSTIC_TEST
Intervention: serum procalcitonin
Description: predicting the severity of intoxication

Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: predicting the severity of intoxication

Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: predicting the severity of intoxication
Study: NCT05141136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound probe sagittal group
Description: Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound probe transverse group
Description: Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
Study: NCT06109493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
Study: NCT06552065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collagen with silk fibroin membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collagen with silk fibroin membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cross linked collagen membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross linked collagen membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
Study: NCT06551441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed.